Can virtual care keep young psychosis patients out of the hospital?
NCT ID NCT04497857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether delivering coordinated specialty care (CSC) via telehealth works as well as standard in-person care for young people (ages 16–35) with early psychosis. Over 12 months, researchers tracked hospitalizations and engagement in 74 participants. The goal was to see if virtual care could improve access and outcomes for this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Coordinated Specialty Care (CSC) delivered via telehealth or in-person
- What this could lead to
- If successful, this could show that telehealth is as good as or better than in-person care for keeping young people with early psychosis engaged in treatment and out of the hospital.
- What could go wrong
- This is a small pilot study (74 people) with no blinding, so results may not apply broadly. Telehealth may not work for everyone, and some participants might prefer or need in-person visits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
74 people
The number who actually took part.
- Started
-
Mar 2022
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
16 to 35 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Between 16 and 35 years of age 2. Able to give informed consent 3. Willing and able to adhere to the study schedule 4. New intakes enrolled in one of the six clinical programs 5. Non-affective (schizophrenia, schizoaffective, schizophreniform) and affective (major depression with psychotic features, bipolar disorder with psychotic features) psychotic disorders with onsets within 5 years of enrollment. Exclusion Criteria: 1\. Known IQ \< 70 based on participant report
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bipolar disorder with psychotic features are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Early Psychosis Intervention Clinic-New Orleans (EPIC-NOLA) - Tulane University
New Orleans, Louisiana, 70119, United States
-
Prevention and Recovery Center for Early Psychosis
Indianapolis, Indiana, 46202, United States
-
Program for Risk Evaluation and Prevention (PREP) - University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Strong Ties Young Adults Program- University of Rochester Medical Center
Rochester, New York, 14623, United States
-
The Early Psychosis Intervention Center (EPICENTER) at Ohio State
Columbus, Ohio, 43210, United States
-
Vanderbilt's Early Psychosis Program - Vanderbilt University
Nashville, Tennessee, 37212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug